Cargando…
Impact of the influenza vaccine on COVID-19 infection rates and severity
BACKGROUND: With a unique influenza season occurring in the midst of a pandemic, there is interest in assessing the role of the influenza vaccine in COVID-19 susceptibility and severity. METHODS: In this retrospective cohort study, patients receiving a laboratory test for COVID-19 were identified. T...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899024/ https://www.ncbi.nlm.nih.gov/pubmed/33631305 http://dx.doi.org/10.1016/j.ajic.2021.02.012 |
_version_ | 1783653985064845312 |
---|---|
author | Conlon, Anna Ashur, Carmel Washer, Laraine Eagle, Kim A. Hofmann Bowman, Marion A. |
author_facet | Conlon, Anna Ashur, Carmel Washer, Laraine Eagle, Kim A. Hofmann Bowman, Marion A. |
author_sort | Conlon, Anna |
collection | PubMed |
description | BACKGROUND: With a unique influenza season occurring in the midst of a pandemic, there is interest in assessing the role of the influenza vaccine in COVID-19 susceptibility and severity. METHODS: In this retrospective cohort study, patients receiving a laboratory test for COVID-19 were identified. The primary outcome was comparison of positive COVID-19 testing in those who received the influenza vaccine versus those who did not. Secondary end points in patients testing positive for COVID-19 included mortality, need for hospitalization, length of stay, need for intensive care, and mechanical ventilation. RESULTS: A total of 27,201 patients received laboratory testing for COVID-19. The odds of testing positive for COVID-19 was reduced in patients who received an influenza vaccine compared to those who did not (odds ratio 0.76, 95% CI 0.68-0.86; P < .001). Vaccinated patients testing positive for COVID-19 were less likely to require hospitalization (odds ratio, 0.58, 95% CI 0.46-0.73; P < .001), or mechanical ventilation (odds ratio, 0.45, 95% CI 0.27-0.78; P = .004) and had a shorter hospital length of stay (risk ratio, 0.76, 95% CI 0.65-0.89; P < .001). CONCLUSION: Influenza vaccination is associated with decreased positive COVID-19 testing and improved clinical outcomes and should be promoted to reduce the burden of COVID-19. |
format | Online Article Text |
id | pubmed-7899024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78990242021-02-23 Impact of the influenza vaccine on COVID-19 infection rates and severity Conlon, Anna Ashur, Carmel Washer, Laraine Eagle, Kim A. Hofmann Bowman, Marion A. Am J Infect Control Major Article BACKGROUND: With a unique influenza season occurring in the midst of a pandemic, there is interest in assessing the role of the influenza vaccine in COVID-19 susceptibility and severity. METHODS: In this retrospective cohort study, patients receiving a laboratory test for COVID-19 were identified. The primary outcome was comparison of positive COVID-19 testing in those who received the influenza vaccine versus those who did not. Secondary end points in patients testing positive for COVID-19 included mortality, need for hospitalization, length of stay, need for intensive care, and mechanical ventilation. RESULTS: A total of 27,201 patients received laboratory testing for COVID-19. The odds of testing positive for COVID-19 was reduced in patients who received an influenza vaccine compared to those who did not (odds ratio 0.76, 95% CI 0.68-0.86; P < .001). Vaccinated patients testing positive for COVID-19 were less likely to require hospitalization (odds ratio, 0.58, 95% CI 0.46-0.73; P < .001), or mechanical ventilation (odds ratio, 0.45, 95% CI 0.27-0.78; P = .004) and had a shorter hospital length of stay (risk ratio, 0.76, 95% CI 0.65-0.89; P < .001). CONCLUSION: Influenza vaccination is associated with decreased positive COVID-19 testing and improved clinical outcomes and should be promoted to reduce the burden of COVID-19. The Author(s). Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. 2021-06 2021-02-22 /pmc/articles/PMC7899024/ /pubmed/33631305 http://dx.doi.org/10.1016/j.ajic.2021.02.012 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Major Article Conlon, Anna Ashur, Carmel Washer, Laraine Eagle, Kim A. Hofmann Bowman, Marion A. Impact of the influenza vaccine on COVID-19 infection rates and severity |
title | Impact of the influenza vaccine on COVID-19 infection rates and severity |
title_full | Impact of the influenza vaccine on COVID-19 infection rates and severity |
title_fullStr | Impact of the influenza vaccine on COVID-19 infection rates and severity |
title_full_unstemmed | Impact of the influenza vaccine on COVID-19 infection rates and severity |
title_short | Impact of the influenza vaccine on COVID-19 infection rates and severity |
title_sort | impact of the influenza vaccine on covid-19 infection rates and severity |
topic | Major Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899024/ https://www.ncbi.nlm.nih.gov/pubmed/33631305 http://dx.doi.org/10.1016/j.ajic.2021.02.012 |
work_keys_str_mv | AT conlonanna impactoftheinfluenzavaccineoncovid19infectionratesandseverity AT ashurcarmel impactoftheinfluenzavaccineoncovid19infectionratesandseverity AT washerlaraine impactoftheinfluenzavaccineoncovid19infectionratesandseverity AT eaglekima impactoftheinfluenzavaccineoncovid19infectionratesandseverity AT hofmannbowmanmariona impactoftheinfluenzavaccineoncovid19infectionratesandseverity |